Credit: Getty Images A discussion of the use of beta-blocker therapy following AMI, with Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD. Beta blockers have long been included in the ...
ST-segment myocardial infarction (STEMI) causes significant morbidity and mortality, with infarct size being the primary predictor of clinical outcome. Given imaging evidence that early IV metoprolol ...
ESTERO, FLORIDA / ACCESS Newswire / September 3, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), developer of a multi-faceted patent-pending drug delivery technology, ...
Background There is a lack of contemporary data describing patients with left ventricular (LV) systolic dysfunction post ...
MULHOUSE, France, and SUNNYVALE, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and BioCardia, Inc.
A new study published in the journal of PloS One showed that although reoperative therapy with evolocumab with rosuvastatin ...
Advanced CKD was linked to a higher likelihood of both fatal and non-fatal adverse outcomes after acute myocardial infarction treatment. Patients with advanced chronic kidney disease (ACKD) with acute ...
Premenopausal women presenting with acute coronary syndrome (ACS) are a unique and often underrecognized patient population. Although they are traditionally considered at lower cardiovascular risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results